ANGLE’s service laboratory provides specialised circulating tumour cell (CTC) enrichment and comprehensive liquid biopsy analysis services
Our mission is to advance the development of new cancer therapies and personalised medicine. We use Parsortix technology to harvest CTCs and CTC clusters for subsequent DNA, RNA and protein expression analysis.
Consult with our scientists to identify the most efficient and effective strategy to meet your project needs
Contact usExpert assay development and custom solutions
Our workflow makes epithelial, mesenchymal and epithelial-mesenchymal transitioning (EMT) CTCs, CTC clusters and cfDNA accessible for downstream analysis. Comprehensive profiling of liquid biopsy samples for drug relevant biomarkers enables longitudinal monitoring of patients and may help to determine:
- Changes in a patient’s biomarker profile over time and in response to treatment
- If the drug is reaching the intended target and inducing the intended response
Our expert team provides a comprehensive solution for the customised analysis of your samples and a service that is tailored to your specifications.
Capabilities include:
Molecular analysis:
- Next generation sequencing (NGS) DNA dual analysis of CTC-DNA and cfDNA from a single blood tube. Our workflow uses CTCs harvested by Parsortix technology combined with Illumina’s Cell-Free DNA Prep with Enrichment kit.
Enumeration, immunofluorescence (IF) and fluorescence in situ hybridisation (FISH):
- Enumeration of epithelial, mesenchymal and epithelial-mesenchymal transitioning (EMT) CTCs and CTC clusters
- DNA Damage Response (DDR) proteins yH2AX, pKAP1 and RAD51, as well as micronuclei detection
- Androgen Receptor protein expression analysis
- PD-L1 protein expression analysis
- Identification of HER2 protein expression by IF and quantification of HER2/neu gene amplification via FISH
We can also undertake bespoke assay development for solid cancers and liquid biopsy applications to meet your specific requirements.
Meet our biopharmaceutical partnerships team
We will work with you to provide the best solution for your project including optimised and standardised workflows to ensure an efficient process and reproducible results.
Brett Swansiger
Chief Commercial Officer
Brett Swansiger is Chief Commercial Officer for ANGLE, and is responsible for managing pharma and clinical services sales and building corporate partnerships globally, and for guiding US research and clinical sales and payer engagement. He also supports the products business teams responsible for sale of products via direct sales and through distributors.
Brett has over 20 years of commercial leadership, international business development, business to business sales, and U.S. managed care contracting experience within the molecular diagnostics and pharmaceutical industries.
Mark Rogers
Senior US Biopharma Partnering Lead
Mark Rogers is a seasoned professional with over two decades of experience in life science and clinical diagnostics. Currently serving as the Senior Sales Manager for BioPharma Services at ANGLE plc, Mark brings a wealth of knowledge to his role. His expertise spans strategic partnerships, diagnostic development, and clinical genomics.
Prior to joining ANGLE, Mark held the position of Global Pharma Alliance Manager at LGC Clinical Diagnostics, a leading provider of precision medicine tools and services. There, he played a crucial role in expanding the company’s reach within the pharmaceutical industry and strengthening its network of diagnostic partners and CROs.
Mark’s career is characterized by his ability to leverage his extensive experience to drive growth and foster meaningful partnerships in the rapidly evolving field of precision medicine. His deep understanding of the industry landscape and strategic approach to sales make him a valuable asset in his current role at ANGLE plc.
Brett Swansiger
Chief Commercial Officer
Brett Swansiger is Chief Commercial Officer for ANGLE, and is responsible for managing pharma and clinical services sales and building corporate partnerships globally, and for guiding US research and clinical sales and payer engagement. He also supports the products business teams responsible for sale of products via direct sales and through distributors.
Brett has over 20 years of commercial leadership, international business development, business to business sales, and U.S. managed care contracting experience within the molecular diagnostics and pharmaceutical industries.
Mark Rogers
Senior US Biopharma Partnering Lead
Mark Rogers is a seasoned professional with over two decades of experience in life science and clinical diagnostics. Currently serving as the Senior Sales Manager for BioPharma Services at ANGLE plc, Mark brings a wealth of knowledge to his role. His expertise spans strategic partnerships, diagnostic development, and clinical genomics.
Prior to joining ANGLE, Mark held the position of Global Pharma Alliance Manager at LGC Clinical Diagnostics, a leading provider of precision medicine tools and services. There, he played a crucial role in expanding the company’s reach within the pharmaceutical industry and strengthening its network of diagnostic partners and CROs.
Mark’s career is characterized by his ability to leverage his extensive experience to drive growth and foster meaningful partnerships in the rapidly evolving field of precision medicine. His deep understanding of the industry landscape and strategic approach to sales make him a valuable asset in his current role at ANGLE plc.
Research Use Only. Not for use in Diagnostic Procedures